Cafepharma Today

May 15 2025 - FDA approves Amneal's self-administered migraine treatment
FDA approves Amneal's self-administered migraine treatment
VC firm reveals plan for 30K-square-foot biotech incubator space in New Jersey
Philips taps Nvidia to build AI model for MRI
FDA delays decision on Biohaven's rare disease drug filing, plans adcomm
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Angion swings for a $36M IPO as biotech's bear turn drags on
Fierce Biotech
Tuesday, April 15, 2014 - 10:57am
tags:
Angion, IPOs
GE Healthcare lands FDA nod for all-in-one CT
Mass Device
Tuesday, April 15, 2014 - 10:55am
tags:
GE Healthcare, FDA, CT Scan, devices, Revolution CT
Ziopharm: Attempting To Rise Again In A Crowded Space
Seeking Alpha
Tuesday, April 15, 2014 - 10:53am
tags:
Ziopharm
Novartis marks 235 admin jobs for deletion amid companywide restructuring
Fierce Pharma
Tuesday, April 15, 2014 - 10:43am
tags:
Novartis, restructuring, layoffs
Puma Biotechnology: ISPY2 Data Added Little To The Neratinib Conversation
Seeking Alpha
Tuesday, April 15, 2014 - 10:40am
tags:
Puma Biotechnology, neratinib, breast cancer
Boehringer 2013 profit up on Pradaxa sales, cost cuts
Reuters
Tuesday, April 15, 2014 - 10:37am
tags:
earnings, Boehringer Ingelheim
Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?
Motley Fool
Tuesday, April 15, 2014 - 10:36am
tags:
hepatitis C, Gilead Sciences, Sovaldi, Merck, Bristol-Myers Squibb, daclatasvir, asunaprevir, MK-5172, MK-8742
Big Pharma's Turn On RNAi Shows That New Technologies Don't Guarantee R&D Success
Forbes
Tuesday, April 15, 2014 - 10:35am
tags:
Big Pharma, RNAi, Novartis, Alnylam
FDA approves Tanzeum to treat type 2 diabetes
Yahoo/Fly on the Wall
Tuesday, April 15, 2014 - 10:34am
tags:
FDA, Tanzeum, type 2 diabetes, diabetes, thyroid cancer, GSK
Will Cymbalta Break Eli Lilly?
Seeking Alpha
Tuesday, April 15, 2014 - 10:11am
tags:
Eli Lilly, Cymbalta, dulaglutide, patents, Evista, China
AbbVie initiates Phase III clinical trial of veliparib in lung cancer
The Fly on the Wall
Tuesday, April 15, 2014 - 10:09am
tags:
AbbVie, clinical trials, veliparib, non-small cell lung cancer
Ranbaxy’s Woes Add $900 Million to U.S. Heart Drug Costs
Bloomberg
Tuesday, April 15, 2014 - 10:05am
tags:
Ranbaxy, generics, Novartis, Diovan
Adverse currency moves hit Roche first-quarter sales
Yahoo/Reuters
Tuesday, April 15, 2014 - 9:30am
tags:
Roche, earnings
J&J beats forecasts as new drugs shine, shares jump
Yahoo/Reuters
Tuesday, April 15, 2014 - 9:29am
tags:
JNJ, earnings
Merck bags FDA approval for its grass pollen pill
Fierce Biotech
Monday, April 14, 2014 - 9:31pm
tags:
grass pollen allergy, FDA, Merck, Grastek
Pipeline Progress at Coronado Biosciences
Yahoo/Zacks.com
Monday, April 14, 2014 - 9:29pm
tags:
Coronado Biosciences, CNDO-109, autism
Drugmakers Oppose Teva Bid to Delay Copaxone Rivals
Bloomberg
Monday, April 14, 2014 - 7:08pm
tags:
Teva, Copaxone, MS, multiple sclerosis, Momenta, generics, Sandoz, Mylan
Novartis to Shire Said to Weigh Bids for ThromboGenics
Bloomberg
Monday, April 14, 2014 - 6:49pm
tags:
Shire, ThromboGenics, Novartis, Roche, Valeant Pharmaceuticals, Regeneron, Allerg
New attention disorder could equal a big new ADHD drug market
Fierce Pharma
Monday, April 14, 2014 - 6:27pm
tags:
Strattera, Sluggish Cognitive Tempo, Shire, Eli Lilly, attention deficit disorder, ADD
Alnylam slips after Novartis reportedly cuts back RNAi development
The Fly on the Wall
Monday, April 14, 2014 - 6:22pm
tags:
Novartis, Alnylan, RNAi

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.